Epstein-Barr virus latent membrane protein 1, latent membrane protein 2, and nuclear antigen 1 peptides presented on MHC class I (EBV LMP1/LMP2/EBNA1-MHC I)

The target consists of specific peptide fragments derived from Epstein-Barr virus (EBV) latent proteins—Latent Membrane Protein 1 (LMP1), Latent Membrane Protein 2 (LMP2), and Epstein-Barr Nuclear Antigen 1 (EBNA1)—presented on the cell surface by Major Histocompatibility Complex (MHC) class I molecules (Young & Rickinson, 2004, Nature Reviews Cancer). These proteins are critical for EBV's ability to maintain latency and transform host cells into malignancies such as nasopharyngeal carcinoma and various lymphomas (Bollard & Heslop, 2016, Blood). LMP1 and LMP2 function as mimics of host cell signaling receptors, while EBNA1 is essential for the replication of the viral episome (Taylor et al., 2015, Journal of Virology). In the context of immunotherapy, these peptide-MHC complexes serve as highly specific targets for cytotoxic T lymphocytes (CTLs), which can be engineered or expanded to recognize and eliminate EBV-positive tumor cells (EMA, 2022, Ebvallo Assessment Report). Targeting these complexes is a primary strategy for treating EBV-associated post-transplant lymphoproliferative disorder (PTLD), though challenges include viral-mediated downregulation of MHC molecules and the need for HLA-matching in allogeneic cell therapies (Hislop et al., 2007, Annual Review of Immunology).

Other names

EBV-specific peptide-MHC complexesLMP1/LMP2/EBNA1-HLA class I complexesEpstein-Barr virus latent antigensEBV-associated tumor-associated antigens

T-cell receptor (TCR) mediated recognition and subsequent cytotoxic T-lymphocyte (CTL) activation leading to apoptosis of target cells (Bollard & Heslop, 2016, Blood).